OmniCyte

Executive Summary

OmniCyte is a preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, dedicated to developing next-generation targeted immunotherapies for cancer. The company leverages its proprietary Immuno-Oncology Platform Technology to engineer recombinant targeted immunomodulators designed to enhance the immune system's ability to recognize and eliminate tumor cells. OmniCyte's initial programs focus on two high-unmet-need indications: ovarian cancer and small cell lung cancer, both of which have limited treatment options and poor prognoses. By employing a modular platform, OmniCyte aims to create a pipeline of novel bispecific and multispecific biologics that can potentially overcome immune evasion mechanisms and improve patient outcomes. As a private, early-stage entity, the company is currently advancing its lead candidates through preclinical development, with an emphasis on demonstrating proof of concept in vivo and establishing a robust safety profile.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead candidate in ovarian cancer40% success
• Q3 2026Preclinical efficacy data presentation at a major oncology conference (e.g., AACR or ASCO)70% success
• TBDAnnouncement of a strategic partnership or licensing deal for platform technology30% success